UNSPSC 51162033: Guaifenesin/sodium citrate/theophylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162033 Guaifenesin/sodium citrate/theophylline is a Commodity code that in recent state and local procurement activity spans pharmaceutical procurement well beyond the narrow scope implied by its name — state and local buyers are actively sourcing naloxone and safe drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products through competitive bidding and cooperative purchasing mechanisms. The issuing bodies reflect a broad cross-section of public entities: county health departments and government agencies (Seminole County, Florida; Hall County, Georgia), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) serving state and local government facilities across multiple jurisdictions including Oregon. Work solicited under the code includes emergency response medications and harm-reduction supplies, employer-sponsored pharmacy benefit administration for government employees, exploration of direct manufacturer contracting to bypass traditional pharmacy benefit manager arrangements, and bulk generic and OTC pharmaceutical procurement for government health systems.

Recent opportunities span Florida, Georgia, Texas, and Minnesota-led multi-state activity. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. Hall County, Georgia released RFQ/P #47-010 on May 4, 2026, to procure on-site pharmacy services for approximately 3,005 eligible individuals enrolled in the county's group health insurance plans, with sealed proposals due June 4, 2026, using an 80/20 scoring structure (800 points for technical qualifications, 200 points for cost). The Texas Health and Human Services Commission issued RFI No. HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs before proceeding to formal RFP. MMCAP posted an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities, with proposals due March 26, 2026, and awards effective July 1, 2026; the RFP weighted price competitiveness at 75 percent of evaluation and required vendors to work through three authorized wholesalers.